Pfizer Inc. and BioNTech SE announced that the FDA has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant… read more.
Pfizer and BioNTech SE announced that the European Commission has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to… read more.
Pfizer announced that the FDA accepted for Priority Review a supplemental New Drug Application (sNDA) for Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with… read more.
Pfizer Japan Inc. and Eisai Co., Ltd. announced that the companies will commence the co-promotion of the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec OD Tablet 75mg… read more.
Pfizer Inc. announced the FDA approved Ibrance (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone… read more.
Pfizer Inc. announced that the FDA has approved an expanded indication for Hympavzi (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and… read more.
Pfizer announced detailed results from the pivotal Phase 3 TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway… read more.
Pfizer announced that the European Commission has granted marketing authorization to expand the approved indication for Hympavzi (marstacimab) to include patients 12 years of age and older weighing… read more.
Pfizer announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating Elrexfio (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at… read more.
Pfizer Inc. announced positive topline results from the Phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an… read more.
Pfizer Inc. announced the FDA has granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux ) and fluorouracil-based chemotherapy for the treatment of adult patients with… read more.
Pfizer Inc. announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating Braftovi (encorafenib) in combination with cetuximab… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
